Market capitalization | $988.95m |
Enterprise Value | $959.91m |
PER (TTM) P/E ratio | 14.43 |
EV/FCF (TTM) EV/FCF | 28.91 |
EV/Sales (TTM) EV/Sales | 2.87 |
P/S ratio (TTM) P/S ratio | 2.96 |
P/B ratio (TTM) P/B ratio | 6.35 |
Sales growth (TTM) Sales growth | 19.20% |
Turnover (TTM) Turnover | $334.51m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
5 Analysts have issued a MiMedx Group, Inc. forecast:
5 Analysts have issued a MiMedx Group, Inc. forecast:
Mar '24 |
+/-
%
|
||
Net profit | 72 72 |
394%
394%
|
|
Depreciation and amortization | 3.60 3.60 |
31%
31%
|
|
Share compensation | 17 17 |
30%
30%
|
|
Operating cash flow | 36 36 |
405%
405%
|
|
Investments | 2.62 2.62 |
18%
18%
|
|
Dividend paid | - - |
-
|
|
Free cash flow | 33 33 |
341%
341%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
MiMedx Group, Inc. is an advanced wound care and an emerging therapeutic biologics company. It engages in developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The company processes the human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx Group was founded on July 30, 1985 and is headquartered in Marietta, GA.
Head office | United States |
CEO | Joe Capper |
Employees | 895 |
Founded | 1985 |
Website | www.mimedx.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.